1. Home
  2. GL vs EXEL Comparison

GL vs EXEL Comparison

Compare GL & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globe Life Inc.

GL

Globe Life Inc.

HOLD

Current Price

$131.30

Market Cap

11.0B

Sector

Finance

ML Signal

HOLD

Logo Exelixis Inc.

EXEL

Exelixis Inc.

HOLD

Current Price

$44.37

Market Cap

11.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GL
EXEL
Founded
1900
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Life Insurance
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.0B
11.1B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
GL
EXEL
Price
$131.30
$44.37
Analyst Decision
Buy
Buy
Analyst Count
10
24
Target Price
$151.50
$44.73
AVG Volume (30 Days)
476.4K
2.5M
Earning Date
10-22-2025
11-04-2025
Dividend Yield
0.82%
N/A
EPS Growth
16.72
53.55
EPS
13.77
2.38
Revenue
$5,940,974,000.00
$2,288,218,000.00
Revenue This Year
$7.51
$9.14
Revenue Next Year
$5.15
$12.51
P/E Ratio
$9.54
$18.67
Revenue Growth
3.73
9.93
52 Week Low
$100.62
$31.90
52 Week High
$147.83
$49.62

Technical Indicators

Market Signals
Indicator
GL
EXEL
Relative Strength Index (RSI) 42.97 63.52
Support Level $129.21 $43.00
Resistance Level $132.02 $44.79
Average True Range (ATR) 2.33 1.03
MACD -0.05 0.06
Stochastic Oscillator 26.80 83.48

Price Performance

Historical Comparison
GL
EXEL

About GL Globe Life Inc.

Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Share on Social Networks: